Fentanyl transdermal absorption linked to pharmacokinetic characteristics in patients undergoing palliative care

Journal of Clinical Pharmacology

Volumn 50, Issue 6, 2010, Pages 667-678

  Van Nimmen, Nadine F J ^a   Poels, Katrien L C ^a   Menten, Joannes J ^b   Godderis, Lode ^a,c   Veulemans, Hendrik A F ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c EXTERNAL SERVICE FOR PREVENTION AND PROTECTION AT WORK   (Belgium)

Author keywords

Absorption; Fentanyl; Monitoring; Pharmacokinetics; Skin

Indexed keywords

FENTANYL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG MONITORING; DRUG URINE LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; URINALYSIS;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN; PALLIATIVE CARE; SKIN ABSORPTION;

EID: 77953733312     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009347872     Document Type: Article

References (24)

1. Grond S., Radbruch L., Lehmann KA Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet. 2000 ; 38: 59-89.
2. Kornick CA, Santiago-Palma J., Moryl N., et al. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf. 2003 ; 26: 951-973.
3. Southwell D., Barry BW, Woodford R. Variations in permeability of human skin within and between specimens. Int J Pharm. 1984 ; 18: 299-309.
4. Solassol I., Caumette L., Bressolle F., et al. Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients. Oncol Rep. 2005 ; 14: 1029-1036.
5. Solassol I., Bressolle F., Caumette L., et al. Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. Ther Drug Monit. 2005 ; 27: 491-498.
6. Gupta SK, Southam M., Gale R., et al. System functionality and physicochemical model of fentanyl transdermal system. J Pain Symptom Manage. 1992 ; 7 (suppl): S17 - S26.
7. Karst M., Fink M., Wagner T., et al. Transdermal fentanyl: little absorption in two patients with systemic sclerosis ? Pain Med. 2001 ; 2: 225-227.
8. Muijsers RB, Wagstaff AJ Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs. 2001 ; 61: 2289-2307.
9. Calis KA, Kohler DR, Corso DM Transdermally administered fentanyl for pain management. Clin Pharm. 1992 ; 11: 22-36.
10. Feierman DE, Lasker JM Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes: role of CYP3A4. Drug Metab Dispos. 1996 ; 24: 932-939.
11. Jeal W., Benfield P. Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. Drugs. 1997 ; 53: 109-138. (Pubitemid 27042235)
12. Scholz J., Steinfath M., Schulz M. Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil: an update. Clin Pharmacokinet. 1996 ; 31: 275-292.
13. Haberer JP, Schoeffler P., Couderc E., et al. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth. 1982 ; 54: 1267-1270.
14. Poklis A., Backer R. Urine concentrations of fentanyl and norfentanyl during application of Duragesic transdermal patches. J Anal Toxicol. 2004 ; 28: 422-425.
15. Van Nimmen NF, Veulemans HA Validated GC-MS analysis for the determination of residual fentanyl in applied Durogesic reservoir and Durogesic D-Trans matrix transdermal fentanyl patches. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 ; 846: 264-272.
16. Van Nimmen NF, Poels KL, Veulemans HA Highly sensitive gas chromatographic-mass spectrometric screening method for the determination of picogram levels of fentanyl, sufentanil and alfentanil and their major metabolites in urine of opioid exposed workers. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 ; 804: 375-387.
17. American Conference of Industrial Hygienists (ACGIH). TLVs and BEIs: Threshold Limit Values for Chemical Substances and
18. Physical Agents & Biological Exposure Indices. Cincinnati, OH: ACGIH ; 2008.
19. Bj¶rkman S., Wada DR, Stanski DR Application of physiologic models to predict the influence of changes in body composition and blood flows on the pharmacokinetics of fentanyl and alfentanil in patients. Anesthesiology. 1998 ; 88: 657-667.
20. Schwartz JB The influence of sex on pharmacokinetics [published erratum appears in Clin Pharmacokinet. 2004;43:732]. Clin Pharmacokinet. 2003 ; 42: 107-121.
21. Rademaker M. Do women have more adverse drug reactions ? Am J Clin Dermatol. 2001 ; 2: 349-351.
22. Meibohm B., Beierle I., Derendorf H. How important are gender differences in pharmacokinetics ? Clin Pharmacokinet. 2002 ; 41: 329-342.
23. Someya T., Shibasaki M., Noguchi T., et al. Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction. J Clin Psychopharmacol. 1992 ; 12: 169-174.
24. Tegeder I., L¶tsch J., Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet. 1999 ; 37: 17-40.